The interest on targeting adenosine A 2A receptors in the realm of psychiatric diseases first arose based on its tight physical and functional interaction with dopamine D 2 receptors. However, the role of central A 2A receptors is now viewed as much broader than just controlling D 2 receptor function. Thus, there is currently a major interest in the ability of A 2A receptors to control synaptic plasticity at glutamatergic synapses. This is due to a combined ability of A 2A receptors to facilitate the release of glutamate and the activation of NMDA. Therefore, A 2A receptors are now conceived as a normalizing device promoting adequate adaptive responses in neuronal circuits, a role similar to that fulfilled, in essence, by dopamine. This makes A 2A receptors a particularly attractive target to manage psychiatric disorders since adenosine may act as go-between glutamate and dopamine, two of the key players in mood processing. Furthermore, A 2A receptors also control glia function and brain metabolic adaptation, two other emerging mechanisms to understand abnormal processing of mood, and A 2A receptors are an important player in controlling the demise of neurodegeneration, considered an amplificatory loop in psychiatric disorders. Current data only provide an indirect confirmation of this putative role of A 2A receptors, based on the effects of caffeine (an antagonist of both A 1 and A 2A receptors) in psychiatric disorders. However, the introduction of A 2A receptors in clinics as antiparkinsonian agents is hoped to bolster our knowledge on the role of A 2A receptors in mood disorders in the near future.